文献速递头颈外科

第八版AJCC分期在经口机器人手术治疗HPV相关口咽癌中的应用

Application of the Eighth Edition American Joint Committee on Cancer Staging System for HPV-Related Oropharyngeal Cancer Treated With Transoral Robotic Surgery.
PubMed 文献 · Laryngoscope · 2017-10-09

该回顾性队列研究纳入2007至2016年接受经口机器人手术(TORS)的110例HPV相关口咽癌(HPV+OPC)患者,至少随访1年。中位随访54个月,总生存率100%,估计3年无病生存率(DFS)为87%(95%CI 77-93)。按第八版AJCC分期,94%患者为I期,病理再分期比例低,且病理I期内无临床病理因素与DFS显著相关。

要点

  • TORS治疗HPV+OPC后总生存率100%,3年DFS为87%。
  • 第八版AJCC分期下94%患者为I期,病理再分期比例低。
  • 病理I期内未发现与DFS显著相关的临床病理因素。

核心结论

  • 多数接受TORS的HPV+OPC患者按第八版AJCC分期为I期,且与旧版分期相比病理再分期有限。
  • 该组患者肿瘤学结局良好,病理I期内无临床病理特征对DFS有显著影响。

研究设计与样本

  • 回顾性队列研究,纳入110例HPV相关口咽癌患者,2007至2016年接受TORS,至少随访1年。
  • 采用Kaplan-Meier法估计3年无病生存率并评估复发差异。

主要发现

  • 中位随访54个月,85%为男性,中位年龄60岁。
  • 24%患者存在包膜外侵犯。
  • 总生存率100%,估计3年DFS为87%(95%CI 77-93)。
  • 第七版AJCC分期下,5%为I期、11%为II期、26%为III期、57%为IVa期;25%患者病理升级,14%降级。

关键数值与推荐

  • 第七版AJCC分期分布:I期5%、II期11%、III期26%、IVa期57%。
  • 第八版AJCC分期:临床和病理分期均有94%患者为I期。
  • 病理再分期:第七版下25%升级、14%降级;第八版下6%升级、6%降级。

临床怎么用

  • 对于接受TORS的HPV+OPC患者,第八版AJCC分期可识别出绝大多数为I期,预后良好。
  • 病理I期内缺乏显著预后因素,提示该组患者可能不需要强化治疗,但需进一步研究。

局限性

  • 回顾性研究设计。
  • 样本量有限(110例)。
  • 单中心经验,随访时间中位54个月。
  • 未报告无病生存的多因素分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Analyze patients treated with transoral robotic surgery (TORS) in the context of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system. METHODS: Retrospective cohort study including 110 human papillomavirus-related oropharyngeal cancer (HPV+OPC) patients with a minimum 1-year follow-up treated with TORS between 2007 to 2016. Kaplan-Meier methods were used to estimate 3-year disease-free survival and assess differences in recurrence. RESULTS: One hundred and ten patients with a median follow-up of 54 months were analyzed. Of those, 85% of patients were male, with a median age of 60. Twenty-two percent of patients received no adjuvant therapy; 43% received adjuvant radiation; and 35% underwent adjuvant chemoradiation. Extracapsular spread was identified in 24% of patients. Overall survival was 100%, with estimated 3-year disease-free survival (DFS) (95% confidence interval) of 87% (77, 93). Under the seventh edition of the AJCC, 5% of patients were stage I; 11% were stage II; 26% were stage III; and 57% were stage IVa. Twenty-seven patients (25%) were upstaged on final pathology, whereas 15 patients (14%) were downstaged. Under the eighth edition of the AJCC, 94% of patients were stage I for both clinical and pathologic staging systems. Six patients (6%) were upstaged on final pathology, whereas six patients (6%) were downstaged. No factors demonstrated statistical significance for DFS. Within pathologic stage I, Kaplan-Meier estimates for DFS did not reach statistical significance. CONCLUSION: The majority of patients undergoing TORS for HPV + OPC are stage I under the eighth edition of the AJCC staging system, with limited pathologic re-staging compared with the prior system. Oncologic outcomes are favorable for this group. No clinicopathologic features are significant for DFS within pathologic stage I. LEVEL OF EVIDENCE: 2b. Laryngoscope, 128:1133-1139, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Badhey AK, Olson A, Kadakia S, et al. Application of the Eighth Edition American Joint Committee on Cancer Staging System for HPV-Related Oropharyngeal Cancer Treated With Transoral Robotic Surgery. Laryngoscope. 2017. PMID: 28990700. doi:10.1002/lary.26948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。